Research programme: viral replication inhibitors - Avexa/CSIRO

Drug Profile

Research programme: viral replication inhibitors - Avexa/CSIRO

Latest Information Update: 01 Jun 2007

Price : $50

At a glance

  • Originator Avexa; CSIRO
  • Class
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Viral infections

Most Recent Events

  • 31 Dec 2006 This collaboration is still active
  • 09 Nov 2005 Preclinical trials in Viral infections in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top